The chemokine landscape: one system multiple shades

Front Immunol. 2023 May 11:14:1176619. doi: 10.3389/fimmu.2023.1176619. eCollection 2023.

Abstract

Leukocyte trafficking is mainly governed by chemokines, chemotactic cytokines, which can be concomitantly produced in tissues during homeostatic conditions or inflammation. After the discovery and characterization of the individual chemokines, we and others have shown that they present additional properties. The first discoveries demonstrated that some chemokines act as natural antagonists on chemokine receptors, and prevent infiltration of leukocyte subsets in tissues. Later on it was shown that they can exert a repulsive effect on selective cell types, or synergize with other chemokines and inflammatory mediators to enhance chemokine receptors activities. The relevance of the fine-tuning modulation has been demonstrated in vivo in a multitude of processes, spanning from chronic inflammation to tissue regeneration, while its role in the tumor microenvironment needs further investigation. Moreover, naturally occurring autoantibodies targeting chemokines were found in tumors and autoimmune diseases. More recently in SARS-CoV-2 infection, the presence of several autoantibodies neutralizing chemokine activities distinguished disease severity, and they were shown to be beneficial, protecting from long-term sequelae. Here, we review the additional properties of chemokines that influence cell recruitment and activities. We believe these features need to be taken into account when designing novel therapeutic strategies targeting immunological disorders.

Keywords: Antagonism; Autoantibodies; CXCL12/HMGB1 heterocomplex; Chemokines; Repulsion; Synergism.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Autoantibodies
  • COVID-19*
  • Chemokines / metabolism
  • Humans
  • Inflammation
  • Receptors, Chemokine / metabolism
  • SARS-CoV-2

Substances

  • Chemokines
  • Receptors, Chemokine
  • Autoantibodies

Grants and funding

The authors would like to thank, for the support received over the years: the Swiss National Science Foundation (3100A0-143718/1 and 141773-RM3); Innosuisse (46411.1 IP-LS); the European Union’s Programs for research technological development and demonstration (INNOCHEM - LSHB-CT-2005-518167 (FP6), DEC-VAC - LSHP-CT-2005-018685 (FP6), ADITEC – 280873 (FP7), and TIMER – 281608 (FP7)); the San Salvatore Foundation; the Novartis Foundation; the Helmut Horten Foundation; the Institute for Arthritis Research; the Gottfried and Julia Bangerter-Rhyner-Foundation; the Ceschina Foundation and the Fratelli Agostino Enrico Rocca Foundation.